Preferred Label : Talimogene Laherparepvec;

NCIt synonyms : OncoVEX GM-CSF; GM-CSF-Encoding Oncolytic Herpes Simplex Virus Vaccine; ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene; T-VEC;

NCIt definition : An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.;

UNII : 07730V90L6;

CAS number : 1187560-31-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1187560-31-1 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Imlygic;

Molecule name : JS1 34.5-hGMCSF 47- pA-;

Codes from synonyms : 477;

Details


Main resources

You can consult :


https://www.ema.europa.eu/medicines/human/EPAR/Imlygic
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Talimogene Laherparepvec
Talimogene Laherparepvec
drug approval
europe
drug interactions
pregnancy
breast feeding
adult
antineoplastic agents
antineoplastic agents
gene therapy
melanoma
neoplasm metastasis
Stage IV Cutaneous Melanoma AJCC v6 and v7
melanoma, cutaneous malignant
Unresectable Malignant Neoplasm
oncolytic viruses
oncolytic viruses
injections, intralesional
herpesvirus 1, human
adjuvants, immunologic
adjuvants, immunologic
drug monitoring
product surveillance, postmarketing
contraception
drug evaluation, preclinical
drug storage
talimogene laherparepvec
genetic therapy
talimogene laherparepvec
talimogene laherparepvec
biological products
biological products

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.